Mayo Clinic

ImmunAid completes Round 1 funding for immune cycle concept

Friday, April 13, 2012 01:51 PM

ImmunAid, a private Australian-based biotech, has successfully completed its first capital raising over $1 million from independent arm's-length investors in the U.S., Europe and Australia.

More... »


NinePoint Medical initiates trial of imaging system for esophagus

Tuesday, March 6, 2012 06:10 AM

NinePoint Medical, a developer of medical devices for in vivo pathology, has initiated a clinical trial to evaluate high-resolution optical imaging of Barrett’s esophagus using its proprietary Nvision VLE Imaging System, which received 510(k) clearance from the FDA earlier this year.

More... »


Complete Genomics to provide whole genome sequencing to Mayo Clinic

Friday, February 17, 2012 01:44 PM

Complete Genomics has been selected by Mayo Clinic's Center for Individualized Medicine to provide outsourced whole human genome sequencing.

More... »

EntreMed names two to board of directors

Tuesday, February 7, 2012 01:07 PM

EntreMed, a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, has appointed Wei-Wu He, Ph.D, executive chairman of its board of directors, and Tak W. Mak, Ph.D, as member of the board of directors.

More... »

Drug improves survival of colorectal cancer patients

Wednesday, January 18, 2012 12:02 PM

Phase II trial results show investigational drug regorafenib slowed the progression of tumors and lengthened the lives of patients with metastatic colorectal cancer, said Mayo Clinic oncologist Axel Grothey, the U.S. trial’s principal investigator.

More... »

Delcath names Gores to medical advisory board

Thursday, December 22, 2011 11:57 AM
Delcath Systems has named Gregory Gores, M.D. to the company's medical advisory board.

More... »

Senesco initiates dosing in SNS01-T study

Thursday, November 3, 2011 10:12 AM

Senesco Technologies has initiated dosing in its phase Ib/IIa clinical study of SNS01-T at the Mayo Clinic in Rochester, MN. The study is an open-label, multiple-dose, dose-escalation study which will evaluate the safety and tolerability of SNS01-T when administered by intravenous infusion to relapsed or refractory multiple myeloma patients.

More... »

Taplmmune, Aeras ink research collaboration

Thursday, November 3, 2011 09:55 AM

TapImmune has signed a research collaboration with Aeras. The overall goal of this collaboration will be to evaluate the efficacy of TAP in concert with novel vaccine vectors encoding TB immunogens under development at Aeras with the aim of advancing suitable candidates to clinical development. Aeras will conduct all pre-clinical development studies at their laboratories in Rockville, MD.

More... »

Oxford BioMedica, Mayo Clinic collaborate in glaucoma research

Monday, October 31, 2011 11:04 AM

Oxford BioMedica has entered into a research and development collaboration with Mayo Clinic to develop a novel gene therapy for the treatment of chronic glaucoma. Under the terms of the agreement, Mayo Clinic and Oxford BioMedica will undertake pre-clinical studies to establish the feasibility of treating glaucoma using Oxford BioMedica's proprietary LentiVector gene delivery technology expressing a COX-2 gene and a PGF-2alpha receptor gene in order to reduce intraocular pressure. The collaboration includes an option for exclusive US rights to license Mayo Clinic's glaucoma technology, which Oxford BioMedica can exercise upon completion of pre-clinical studies under confidential terms agreed by Mayo Clinic and Oxford BioMedica.

More... »

Cardio3 establishes US subsidiary

Friday, September 23, 2011 10:35 AM

Belgian cardiac cell therapies firm Cardio3 BioSciences established a U.S. subsidiary in Rochester, MN, to support its clinical and development activities and to bolster existing links with the Mayo Clinic and other U.S. collaborators, according to GEN News. Cardio3’s lead product, C3BS-CQR-1 is a stem cell-based cardiac lineage in clinical development for the treatment of heart failure. Phase III studies are projected to start in 2012.

More... »


CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks worldwide toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs